Experimental models of cryptococcosis. by Sabiiti, W et al.
Hindawi Publishing Corporation
International Journal of Microbiology
Volume 2012, Article ID 626745, 10 pages
doi:10.1155/2012/626745
Review Article
Experimental Models of Cryptococcosis
Wilber Sabiiti, Robin C. May, and E. Rhiannon Pursall
School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Correspondence should be addressed to E. Rhiannon Pursall, r.pursall@bham.ac.uk
Received 19 July 2011; Accepted 4 August 2011
Academic Editor: Julian R. Naglik
Copyright © 2012 Wilber Sabiiti et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cryptococcosis is a life-threatening fungal disease that infects around one million people each year. Establishment and progression
of disease involves a complex interplay between the fungus and a diverse range of host cell types. Over recent years, numerous
cellular, tissue, and animal models have been exploited to probe this host-pathogen interaction. Here we review the range of
experimental models that are available for cryptococcosis research and compare the relative advantages and limitations of the
diﬀerent systems.
1. Introduction
Cryptococcosis presents in three forms—cutaneous, pul-
monary, and meningococcal—and is a life-threatening fun-
gal disease. Although the genus Cryptococcus contains more
than 50 species of free-living basidiomycete fungi, only
two, C. neoformans and C. gattii, are significant pathogens
of humans [1, 2]. Disease is typically caused in the
immunocompromised, such as HIV/AIDS or organ trans-
plant patients, and is usually attributable to C. neoformans.
However, incidences of cryptococcosis in otherwise healthy
individuals have been rising, and C. gattii is primarily
responsible for these cases [2, 3]. Cryptococcal infection is
acquired through inhalation of basidiospores or desiccated
yeast cells into the lungs, from where cryptococci can
potentially disseminate to all organs but with a predilection
to the brain [1, 4–8]. Cryptococcal meningitis is estimated to
kill 600,000 people annually worldwide, with more than 80%
of deaths occurring in Sub-Saharan Africa [9].
In the course of infection through airways to lungs and
from lungs to brain, Cryptococcus must overcome two major
barriers: the innate and adaptive immune mechanisms of
the host. The former consists of anatomical or physical
barriers such as the mucosal or lung epithelium, the blood-
brain barrier of the CNS, and phagocytic cells such as
neutrophils, monocytes/macrophages, and dendritic cells.
Successful evasion of the host defences results in cryptococcal
colonization of host tissues and hence cryptococcosis. To
better understand the pathogenesis of this disease, numerous
in vivo and in vitromodels have been developed to investigate
features of cryptococcosis and address questions such as the
course of cryptococcal infection, invasion of cellular bar-
riers, and interactions with—and evasion of—the immune
response.
The aim of this review is to present all reported exper-
imental models of Cryptococcosis and summarise recent
and/or prolific discoveries using these. This will hopefully
provide an evaluation of how diﬀerent models can aid
Cryptococcal research and give food for thought on how
current and new models could be utilised in novel ways.
2. In Vitro Cellular Models
2.1. Monocytes and Macrophages. The role of monocytes
and macrophages in cryptococcosis has been widely stud-
ied. Macrophages detect, phagocytose and kill extracellular
microorganisms, and present antigen to T cells [10, 11].
These disease factors have been explored using in vitro
models.
Macrophage phagocytosis of nonopsonised cryptococcal
cells is very poor, but dramatically enhanced by complement
or immunoglobulin-based opsonins [12]. Dysfunctional
phagocytic apparatus cripples the immune response; for
example monocytes from HIV/AIDS patients that were
unable to phagocytose cryptococci failed to induce lympho-
proliferative response in a macrophage—lymphocyte cocul-
ture system [13]. Once Cryptococcus cells have been engulfed,
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macrophages can present Cryptococcal antigen and induce
IL-1 expression and T-cell proliferation in vitro [14, 15].
However, cryptococci show a remarkable ability to survive
and proliferate within macrophages, an adaptation that has
been explored using both live imaging (Figure 1) [16–19]
and gene expression [20, 21] approaches in macrophage cell
lines (including J774 and RAW) and primary cells (including
bone-marrow-derived murine cells and peripheral blood
monocyte-derived human cells) [16, 17, 20, 22–24]. A
noteworthy consideration when using in vitro models is that
the Cryptococcus-cell interaction can diﬀer depending on
the type of macrophage used. For example, cryptococcal
expulsion rates were found to be significantly higher in
human primary macrophages compared to the J774 cell line
[17]. However, despite the fact that diﬀerent macrophage
types are known to vary significantly in their behaviour in
vivo [25], this aspect has yet to be extensively investigated in
the context of cryptococcosis.
2.2. Dendritic Cells. Dendritic cells (DCs) constitute vital
mediators of the initiation of adaptive immune response
[26] and are regarded as professional antigen presenters.
Although less well studied than macrophages, several aspects
of DC function have been documented in vitro. Phagocytosis
of live and heat-killed cryptococci and antigen presentation
have been demonstrated in both human peripheral blood
mononuclear cells (PBMCs), derived DCs and mouse bone-
marrow-derived dendritic cells (BMDCs) [27, 28]. Internal-
ization of live C. neoformans induced minimal TNF-alpha
production by human monocyte-derived DCs and none in
mouse-derived BMDCs, whereas humanDCs incubated with
acapsular cryptococci produced significantly higher amounts
of TNF-alpha. This suggests that presence of capsule inhibits
protective cytokine production. While it is clear from these
studies that DCs can internalize and process both dead and
live cryptococci, it is not known whether both dead and
live antigen induce the same type and intensity of cytokine
response. In addition, it is as yet undetermined whether
intracellular cryptococci are eradicated by DCs or whether
they survive, proliferate, and escape as seen in macrophages.
2.3. Neutrophils. Neutrophils make up the largest population
of phagocytes and are the first to be recruited to areas
of infection. However their short lifespan means that they
are a challenging cell type used in in vitro experimen-
tation. Despite this limitation, investigations have shown
that neutrophils are able to kill cryptococci in vitro [29,
30]. Although neutrophil cryptococci killing is typically
considered to be mediated by the oxidative burst, neutrophils
retain partial anticryptococcal function even when treated
with respiratory burst inhibitors [31]. Unlike macrophages,
neutrophils are also able to control extracellular cryptococci
[32], although cryptococci produce mannitol, superoxide
dismutase, and other ROS scavengers which help protect
against extracellular killing by the respiratory burst [32, 33].
To date, however, it is not known whether cryptococci
can persist to any degree within neutrophils, or how this
interaction is modulated by the presence of macrophages at
the infection site.
Figure 1: Cryptococcus neoformans can proliferate to a density
of hundreds of yeast cells within macrophages. Here a J774
macrophage has been partially lysed to reveal intracellular C.
neoformans after 18 hr of incubation. Image: W. Sabiiti.
2.4. Eosonophils. Eosonophils, mostly associated with
inflammatory response to helminthic parasites, have
also been shown to be capable of phagocytosing and
killing C. neoformans [34, 35]. Cryptococcus—eosonophil
interactions have been studied using primary rat peritoneal
eosinophils, in which it has been demonstrated that uptake
of cryptococcal cells is strongly enhanced by antibody
opsonization and is mediated by FcγRII and CD18 [34, 35].
Garro and colleagues further showed that coincubation of C.
neoformans-stimulated eosinophils with CD4+ and CD8+ T
cells from infected mice resulted in proliferation of T cells in
an MHC 1- and 2-dependent manner, and hence eosinophils
can act as antigen presenters and induce adaptive immune
response to cryptococcal infection [35].
2.5. Lymphocytes. Lymphocytes, particularly CD4+ T cells,
are important in the cell-mediated immune response to
cryptococcosis [36]. Lymphocyte—Cryptococcus interaction
models have used either primary mouse-derived or human
PBMC-derived T lymphocytes and, to a lesser extent,
immortalized T-cell lines. Studies using human lympho-
cytes have demonstrated a direct interaction between C.
neoformans and lymphocytes. Both T cells and NK cells
attach to Cryptococcus and directly inhibit its growth in vitro
[36, 37]. Lymphocyte—Cryptococcus conjugate formation
was enhanced when lymphocytes from mice immunized
with heat killed C. neoformans were coincubated with
cryptococcal yeast cells [38], suggesting that prior exposure
activates this process, presumably through antigen process-
ing and presentation by phagocytes to lymphocytes [39].
Intriguingly, both CD4+ and CD8+ T lymphocytes can
kill extracellular cryptococci via granulysin, NK cells utilise
perforin to achieve the same ends [40–43].
3. In Vitro Physical Barrier Models
3.1. Lung Epithelium. The inhalation route of infection
makes the lung the first internal organ to be colonized
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by Cryptococcus. The interaction between Cryptococcus and
epithelial cells lining the alveolar spaces is thus critical in
regulating cryptococcal entry into the circulation system.
Themechanisms that allowCryptococcus to penetrate human
alveolar cells remain largely uncharacterised. Initial investi-
gation showed that glucuronoxylomannan is an important
factor permitting the attachment of yeast to host cell
and subsequent infiltration of, and damage to, the host
intracellular environment [44]. In vitro experiments have
also provided insight into how the capsule virulence factor
promotes the ability of Cryptococcus to cause infection at the
lung barrier. Human lung epithelial cells can internalize both
encapsulated and acapsular strains of C. neoformans [45].
The lung surfactant protein-D (SP-D) was shown to bind to
and promote phagocytosis of both encapsulated and acap-
sular C. neoformans by macrophages in vitro [46]. However,
encapsulated cryptococci are not eﬃciently opsonized by SP-
D and those that were phagocytosed resisted intracellular
killing by macrophages [47]. In addition, the lung is the site
of granuloma formation during pulmonary cryptococcosis
(and potentially during latent infections). To date, however,
no models have been established to address the role of lung
epithelial cells in granuloma formation.
3.2. Blood-Brain Barrier. Cryptococcal meningoencephalitis
is the most devastating and fatal form of cryptococcosis.
Modelling the blood-brain barrier (BBB) with the appropri-
ate neurovascular properties has been a prominent challenge
in cryptococcosis research. Isolation of human, rat and
mouse brainmicrovascular endothelial cells (BMECs), which
can be propagated in vitro to monolayers with BBB-like
properties, has greatly improved the study of Cryptococcus—
BBB interactions (Figure 2). Both human and mouse
immortalized BMEC cell lines are commercially available and
have been used in several studies, although freshly isolated
BMECs are not so readily accessible.
Cryptococcus must penetrate the blood-brain barrier in
order to cause meningococcal infection. Several studies using
either primary or immortalized human, rat and mouse
BMEC as BBB models have shown that BMEC can associate
with and internalize yeast cells [39, 48–50]. Transwell
chamber systems with BMEC monolayers have been used
in some of the studies to demonstrate the occurrence of
transcytosis across this cell layer [39, 50]. However in vivo
the BBB is a complex tissue in which BMECs are supported
by pericytes and astrocytes, a feature which cannot at present
be recreated in vitro. In this context, the recent application of
intravital imaging to examine cryptococcal traversal across
the BBB in vivo represents a major advance for the field [51].
4. In Vivo Models
In vivo models can complement results of in vitro studies
and also stand alone as valuable tools with which to make
new discoveries and test out hypotheses. In this context, it is
important to make the distinction between models that are
used because they are vectors or carriers of human disease,
and those that are used purely for their amenability in an
experimental context. Those that are studied because they
naturally harbour Cryptococcus, for example the koala [52],
will not be discussed here. Instead we concentrate below
on the range of model organisms exploited to undertake
a whole-organism approach to studying Cryptococcus. In
addition, the use of invertebrate models is an increasingly
popular approach in many areas of biomedical research,
including that of human fungal pathogens. We place a
relatively large focus on these novel, emerging models over
the more established and well-used vertebrate systems in
order to highlight potential avenues for exploiting new
model systems for cryptococcal research.
4.1. Invertebrate Models. Invertebrates can be excellent mod-
els for disease. Advantages over their mammalian coun-
terparts include reduced maintenance costs, fewer ethical
restrictions, relatively short reproduction times, and large
brood sizes. A key argument for the use of invertebrate
models is that features of their immune systems allow rig-
orous investigation into human disease. Whereas vertebrates
have evolved innate and adaptive immunity, invertebrates
possess only the innate system, the most ancient form of
pathogen defence. The basic underlying mechanisms of
immune response can therefore be studied without potential
confusion from adaptive immunity, which can be very
species- or even individual-specific.
A well-rehearsed argument that doubts the degree to
which invertebrate models can be of value in biomedical
research centres on the concept that the human immune
system is vastly diﬀerent from the invertebrate system.
Indeed, adaptive immunity allows hosts to recognisemolecu-
lar details of diﬀerent invading pathogens, construct specific
proteins to fight them, and maintain these proteins to
protect against subsequent infections. However despite its
lack of immune memory, the innate system of invertebrates
is highly sophisticated and intricate and does not simply
involve the same stereotypical response to every pathogen it
encounters [53, 54]. Studies from organisms that use only
innate immunity have demonstrated the complexity of this
immune response [55, 56], and how it can vary according to
a range of biotic and abiotic factors.
In addition, many human pathogens probably evolved
their virulence mechanisms in more primitive organisms
[57–60]. In the case of Cryptococcus sp., these primitive
hosts could have included free-living nematodes and amoe-
bae. Adaptations that allowed the pathogens to escape
natural invertebrate predators could have been translated
into virulence factors for infecting mammalian hosts, and
therefore studying interactions between the invertebrates
and microbes could elucidate valuable information about
disease.
Invertebrates are also simple and eﬃcient models in
which to study fungal virulence factors, such as capsule
growth and melanin production [59, 61]; morphological
dimorphism [62]; phospholipase production [63]. Antifun-
gal activity can also be tested rapidly and economically
using invertebrate models, due to their amenability to high-
throughput screens of chemical libraries that can measure
key factors in drug development including host immune
response, eﬃcacy, and toxicity [64, 65].
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Figure 2: Fluorescence microscopy to determine adherent and internalized Cryptococcus neoformans on brain microvascular endothelial
cells. C. neoformans serotype A strain H99 cells were prestained with FITC (green) before 4 hr incubation with brain endothelial cells and
then counterlabelled with Calcofluor White (blue) to label extracellular adherent yeasts. (a) Merged image to reveal both endothelial cells
and associated yeast cells, (b) and (c) Fluorescence images revealing the FITC and Calcofluor stained yeast cells, respectively.
4.1.1. Caenorhabditis elegans. Caenorhabditis elegans has
been employed for immunological study of many pathogens,
and the past decade has seen it established as a model
for Cryptococcus neoformans infection [61]. In this system
a culture of C. neoformans in YPD liquid media is spread
onto agar plates, usually with the addition of antibiotics,
and incubated overnight. When C. elegans are transferred to
these plates they acquire the pathogen orally, leading to fatal
disease [66]. Critical similarities exist between pathogenicity
in C. elegans and mammalian hosts, for example strains of
Cryptococcus with reduced virulence in mammalian hosts
generally show similar attenuation in C. elegans [61]. These
parallels support the case for C. elegans constituting a
sound model for investigating basic mechanisms underlying
Cryptococcus infection, disease, and treatment.
The molecular basis of infection and disease can be
rigorously investigated in C. elegans, due to its amenability
as a genetic model, and consequently a wealth of knowledge
has been accumulated concerning immunity at the gene level.
The potential to screen large numbers of mutant pathogens
in C. elegans and identify genes important for virulence
demonstrates a particular strength for the nematode model.
A recent investigation identified mutations in C. neoformans
that caused reduced survival in ex vivo cerebral spinal
fluid and commensurate attenuation in C. elegans and the
rabbit [67]. In addition, genes important for C. neoformans
virulence in mammalian systems have been shown to be
instrumental in causing death in C. elegans killing assays,
highlighting a parallel between the immunity and patho-
genesis of the Cryptococcus-human and Cryptococcus-worm
model systems. For example, C. neoformans genes associated
with virulence in both mammalian and nematode models
include those associated with signal transduction pathways
(GPA1, PKA1, PKR1, RAS1), laccase production (LAC1), and
the {alpha}mating type [61].
C. elegans can use nonpathogenic forms of Cryptococcus,
for example C. laurentii and C. kuetzingii, as a food source
in the laboratory [23]. This lends support to the theory
that the nematode is a natural predator of Cryptococcus and
could therefore be an ideal model in which to investigate
the evolution of virulence factors that have enabled certain
strains of Cryptococcus to become pathogenic to worms and
other hosts.
However, a profound limitation of C. elegans as a
model for investigating pathogenesis of mammalian disease
is that the mode of infection is completely diﬀerent to
that in mammals. The nematode ingests the pathogen, and
cryptococcal growth is restricted to the intestine, in marked
contrast to the lung inhalation and subsequent dissemination
that is characteristic of human infections. Along with the
limitations associated with this entirely diﬀerent mode of
infection, it is not possible to administer an exact pathogen
dose in this model, which could severely constrain the scope
of certain experiments. In addition, phagocytes are not
present in C. elegans, so in terms of studying phagocytosis
in a whole organism model a more favourable invertebrate
model may be an insect or amoeba.
4.1.2. Amoeboid Models. Soil amoebae are environmental
reservoirs of human pathogens [68] and therefore show
promise as model hosts in the laboratory setting. Amoebae
feed by phagocytosis of microorganisms, in a process that is
essentially similar to the phagocytosis of microbes by human
macrophages [69]. Amoebae therefore provide a simple
model in which to investigate aspects of this fundamental
immune response. Additionally, there are a number of char-
acteristics that make these organisms valuable experimental
models, primarily with respect to genetic tools.
Acantamoeba castellanii. In terms of using invertebrate hosts
to study evolution of human pathogen virulence, the inter-
action between Cryptococcus sp. and A. castellanii provides
interesting and unique opportunity for investigation.Crypto-
coccus can cause amoebae to lyse following phagocytosis [70],
and a popular theory postulates that this adaptation to over-
come predation could have been a precursor to the escape
from mammalian phagocytes that cryptococci demonstrate
in vitro [71]. In support of this, characteristics that promoted
Cryptococcus survival in A. castellanii were also identified
as virulence factors that enhanced Cryptococcus parasitism
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in macrophages [71]. Although A. castellanii may not be
as genetically well characterised as the amoeboid model
D. discoideum, the former has the advantage of remaining
viable in laboratory conditions above 25◦C, therefore more
accurately simulating conditions of human infection, which
occur in the critical 32–37◦C window [72].
An important feature of the A. castellanii model is that
this organism is killed by Cryptococcus. On a basic level
this suggests that Cryptococcus readily acts as a pathogen
in amoebae, which could confer an advantage over another
invertebrate, such as D. melanogaster, which is not killed by
injection of Cryptococcus and therefore may not be such a
valuable a model of pathogenesis.
Dictyostelium discoideum. Dictyostelium discoideum has
proved a useful tool for studying intracellular proliferation
of human pathogens including Cryptococcus. The small
haploid genome of D. discoideum has been sequenced
[73], and is particularly amenable to genetic manipulation
[68, 74].
Important parallels in terms of cryptococcal virulence
are present between D. discoideum and human hosts. For
example the fungal capsule is important for C. neoformans
infection of D. discoideum, as acapsular mutants did not
replicate in the amoebae [59]. Another important finding
in D. discoideum showed that C. neoformans caused disease
with increased eﬃciency following growth in the amoeboid
model, indicating that adaptations for survival in the host
translated into virulence factors [59].
4.1.3. Insect Models. After pathogen recognition, the insect
immune response follows a characteristic sequence of
events involving two major classes of eﬀector systems—
cellular and humoral [75, 76]. The humoral immune
response concerns the production of antimicrobial pep-
tides and induction of enzyme cascades which function
to minimise harm caused by the pathogen. Circulating
haemocytes within the insect haemocoel produce the cel-
lular response and rapidly fight the pathogen using three
key cellular defences: phagocytosis, nodule formation, and
encapsulation [77, 78]. Assays to measure insect immune
response can be applied to a variety of species and
employed in a high-throughput manner. For example, in
vivo phagocytosis can be assessed by nondestructive extrac-
tion of haemolymph containing phagocytosed pathogens
from insects and then analysed using in vitro assays.
Given the importance of phagocytosis in cryptococcosis
research, insects may therefore prove a valuable experimental
tool.
Despite the many advantages of insect models for human
disease research, there are a number of important limitations.
Insects lack most organs found in humans, such as lungs,
kidneys, and hearts. Given that organs such as the lungs
are particularly important in Cryptococcus infection and
disease, this highlights an obvious limitation of insects
rather than mammalian models for this fungal pathogen.
In a similar vein, the blood-brain barrier is a particularly
important area of investigation for Cryptococcus research,
but the lack of blood capillaries in the insect body means
that this aspect of the disease cannot be studied in insect
hosts.
Galleria mellonella. The larvae of the greater wax moth,
Galleria mellonella, have been used as whole-organism vir-
ulence models for various species of pathogenic fungi. This
organism can live at mammalian body temperature, thereby
allowing temperature-sensitive investigation of pathogenesis.
The larva also provides a good infection model because it
is easy to inoculate with specific doses of fungal pathogen,
owing largely to its size (approximately 1.5–2.5 cm in length),
which contrasts with the smaller size of insects such as
Drosophila, in which controlling dose per insect is challeng-
ing [79]. To date, the G. mellonella model has primarily
been used to assess virulence and/or antifungal activity.
Inoculation of microbes into the haemocoel is minimally
invasive because piercing of the haemocoel is not required.
Instead applying gentle pressure can open up the base of the
proleg, and a needle is inserted. The aperture reseals on the
release of pressure [79]. This nonpiercingmethodmeans that
immune response directed at wound repair does not aﬀect
the results of experiments, which would be the case if insects
were injected through the cuticle.
G. mellonella has been advocated as a particularly good
model for diseases that disseminate through the body via the
bloodstream, such as Cryptococcus neoformans and Candida
albicans [79]. The development of G. mellonella as a model
for Cryptococcus neoformans was first achieved by Mylonakis
and colleagues in 2005 [80]. All C. neoformans strains tested
caused death of the insect host, despite eﬀective phagocytosis
by insect haemocytes [80]. This suggests that Cryptococcus
virulence may rely on the same mechanisms in G. mellonella
as it does in in vitro assays, during which the phagocytic
immune response is evaded and even exploited by the
pathogen.
Recently the G. mellonella system was employed to
investigate whether the antifungal activity of Fluconazole
could be enhanced with the addition of other drugs.
Fluconazole proved to have greater beneficial eﬀect for
G. mellonella survival when administered in combination
with the antihistamine Astemizole and a closely related
analog (A2) [81]. The results of this in vivo study were
supported and enhanced by an in vitro experiment, in which
the usually fungistatic Fluconazole became fungicidal when
combined with Astemizole and A2 [81]. This investigation
demonstrates how survival data from an insect model that
is relatively easy to infect and monitor in a high-throughput
manner can support in vitro mechanistic discovery.
Drosophila melanogaster. Infection of D. melanogaster with
C. neoformans can be achieved by a variety of methods, and
both dissemination of disease and local infection can be
investigated. Injection into the haemocoel is done using a
small needle inserted into the thorax or abdomen (e.g., [23]).
This represents a systemic infection because the pathogen is
administered directly into the haemolymph. A limitation of
this method is that it is far removed from the natural pathway
of infection, as microorganisms such as Cryptococcus would
not be able to cross the insect cuticle unless an opening was
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already present. An alternative method is to administer the
pathogen by incorporating it into the fly food.
Interest in D. melanogaster as a model of human disease
has grown in recent years, with the continuing realisation
that immune signalling pathways are highly conserved
between fly and human [82, 83]. Of particular relevance
to fungal disease is the finding that Toll receptor activation
downstream of fungal infection leads to the production of
antifungal peptides by D. melanogaster [84].
Wild-type D. melanogaster shows resistance to fungal
pathogens administered by injection into the haemocoel
including Candida albicans, Aspergillus fumigatus, and Cryp-
tococcus neoformans. Experiments have shown that the Toll
pathway is crucial in this resistance [84, 85]. In contrast,
the Toll pathway is not involved in pathogen defence when
the method of Cryptococcus neoformans infection is ingestion
[85]. This research using Drosophila has suggested that
Cryptococcus neoformans may elicit diﬀerent responses in the
systemic- and digestive-related immunity, in this host at least
[85].
4.2. Vertebrate Models. For certain elements of fungal path-
ogen research, the benefit of the adaptive immune system of
vertebrates will always be a feature that renders them more
valuable as models than invertebrates. Vertebrate models
have been extensively covered in other reviews (e.g., [86, 87])
but are discussed briefly below.
4.2.1. Mouse (Mus musculus). The majority of Cryptococcus-
related work utilising mammalian systems has been carried
out using mice. Due to the fact that murine models are
well established as valuable study systems in many research
areas including fungal pathogenesis, an in-depth discussion
of mice inCryptococcus research is not within the scope of the
present review. Briefly, however, mouse models are a popular
choice because they are well established and characterised in
medical research, and a variety of genetic backgrounds are
available. Infection with Cryptococcus can be achieved by a
variety of methods, including intranasally, intraperitoneally,
intracerebrally, intravenously, intratracheally, and via inhala-
tion [88, 89], which opens up a range of experimental
opportunities. In addition, the vast array of information
available on the mouse immune system means that parallels
and pitfalls can be readily identified, allowing for the design
of highly refined experiments.
4.2.2. Rat (Rattus rattus). The rat model is comparable
to mouse, but with a few advantages. The slightly larger
body size allows a variety of experimental manipulations
to be achieved with relative ease, including endotracheal
intubation, bronchoalveolar lavage, serial venepuncture, CSF
collection, radiography, computed tomography (CT), and
magnetic resonance imaging (MRI) [88]. The rat has also
been reported to develop chronic pulmonary cryptococcosis
in the wild [90], suggesting this organism as a potentially
valuable disease model. A model mimicking pulmonary
cryptococcosis establishment, induced by C. gattii intra-
tracheal inoculation in immunocompetent rat hosts, was
recently established [88]. This opens up the opportunity
to use this model to study more complex elements of
cryptococcal etiology, such as long-term latency or the
emergence of C. gattii as a primary pathogen. The rat
model has been very useful in research into mammalian host
responses to Cryptococcus. For example expression of acidic
mammalian chitinase (AMCase) in response to infection by
Cryptococcus, which contains chitin in its cell wall, could be a
potential mediator of asthma [91].
4.2.3. Guinea Pig (Cavia porcellus). The Guinea pig model
was first established for cryptococcal disease relatively
recently by Kirkpatrick et al. [92]. The larger size of Guinea
pigs compared to mice means they are ideal for more sen-
sitive experimental manipulation. For example, intravenous
inoculation can be relatively easily achieved in Guinea pigs.
Another benefit of the Guinea pig model for fungal research
is that oral doses of antifungals suﬃcient to control fungal
infections are similar to the doses in humans [93]. An
example of the utilisation of the Guinea pig model is the
investigation into the eﬀectiveness of an intravenous delivery
of the antifungal itraconazole in fighting disseminated fungal
infections including cryptococcosis [93].
4.2.4. Rabbit (Oryctolagus cuniculus). The rabbit has been
advocated as a model for cryptococcal meningitis mainly due
to its size in comparison to other mammalian study systems.
For example, Steen et al. [94] chose the rabbit model because
its relatively large body size enables the study of yeast at the
site of infection, which is more diﬃcult in smaller mammals
such as mice and Guinea pigs. Historically the rabbit
model was not an appealing choice for cryptococcal disease
research because the organism appeared to be naturally
resistant to this pathogen [95]. However the potential for this
model increased when pretreatment with corticosteroids and
subsequent Cryptococcus inoculation successfully resulted in
the development of chronic cryptococcal meningitis [95]. A
recent utilisation of this model involved measuring survival
of Cryptococcus mutants in rabbits to establish whether
mutations causing reduced attenuation in cerebral spinal
fluid showed corresponding reduced virulence in vivo [67].
This is an example of the use of a whole-organism model to
validate hypotheses of disease attenuation developed from in
vitro experiments.
4.2.5. Zebrafish (Danio rerio). The zebrafish is emerging
as an attractive model system for a variety of human
diseases. Mutagenesis and screening can be done on a large
scale with the zebrafish, which is a fairly unique feature
in vertebrate models. Another benefit to this model is
that it can be maintained at relatively low cost, with few
ethical restraints. Thus the zebrafish in many ways has the
economical advantages of an invertebrate model whilst also
possessing all of the vertebrate immune system features that
researchers in fungal pathogenesis require.
The zebrafish has not yet been used to investigate infec-
tion and disease in relation to Cryptococcus—however this
application is under development (Figure 3). This model has
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Figure 3: Zebrafish embryo 48 hours after infection with Crypto-
coccus neoformans strain H99 expressing GFP. Image Courtesy of S.
A. Johnston, University of Birmingham, UK. GFP-expressing yeast
was developed by Voelz et al. [99].
been used for other human fungal pathogens, lending hope
to the idea that a disease model for Cryptococcus could soon
be developed. For example, a comprehensive infectionmodel
of the zebrafish with Candida albicans has been established,
in which pathogen morphogenesis and gene expression, and
host immune response, weremonitored [96]. Fish were killed
byC. albicans in a dose-dependentmanner, and infection was
established at a number of diﬀerent sites, indicating that this
organism could be a valuable tool in fungal research.
5. Ex Vivo Models
Ex vivo organ culture could be considered a way of achieving
a balance between the advantages of in vitro and in vivo
experimental models. The use of perfused organs provides
a relatively authentic physiological environment and permits
the study of pathogens crossing membranes, disseminating
through host tissue, and migrating to the bloodstream—
processes not captured by in vitro experimentation. Organs
from higher animals, which would otherwise carry enor-
mous ethical and economic implications, can be studied
when perfused organs are chosen over whole animal models.
For example, haemoperfused liver from pigs was recently
established as a model for C. albicans investigation [97].
This model could be adapted for the study of other human
fungal pathogens including Cryptococcus. An ex vivo model
has also been established for swine trachea [98], and since
Cryptococcus infects the lungs, this model could be of
particular interest to adapt for investigation of this pathogen.
6. Closing Remarks
Cryptococcal research utilises a diverse range of experi-
mental model systems, spanning from individual cells to
unicellular whole organisms tomammalianmodels. Progress
from hereon may benefit from diﬀerent research disciplines
exchanging knowledge and skills so that models already
established in one field, such as drug development, can
be adapted for another area of research such as pathogen
evolution.
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